| pubmed-article:7521901 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7521901 | lifeskim:mentions | umls-concept:C0166049 | lld:lifeskim |
| pubmed-article:7521901 | lifeskim:mentions | umls-concept:C0005768 | lld:lifeskim |
| pubmed-article:7521901 | lifeskim:mentions | umls-concept:C0005795 | lld:lifeskim |
| pubmed-article:7521901 | lifeskim:mentions | umls-concept:C2826293 | lld:lifeskim |
| pubmed-article:7521901 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7521901 | pubmed:dateCreated | 1994-10-11 | lld:pubmed |
| pubmed-article:7521901 | pubmed:abstractText | The clinical significance of hepatitis C antibodies (anti-HCV) in a healthy population was studied by liver function tests and liver biopsies. The patient population consisted of 195 (96.1%) of the 203 blood donors found to be either anti-HCV positive or indeterminate by a recombinant immunoblot assay (RIBA) during the first year of anti-HCV screening of 307,606 donors in Finland using a first generation enzyme-linked immunosorbent assay. Alanine aminotransferase (ALT) levels in 67 donors reacting positively and in 128 reacting indeterminately by a second generation RIBA (RIBA-4) were monitored to evaluate the prevalence of liver damage. Serum N-terminal type III procollagen (PIIINP) concentrations were measured in all donors who fulfilled our criterion for possible hepatitis C (ALT values over two times the normal upper limit on two occasions or over five times the normal upper limit on one occasion) and in 23 randomly selected RIBA-4 positive donors without ALT abnormalities (control group). Two (1.6%) of the RIBA-4 indeterminate donors had ALT values compatible with possible hepatitis C (negative by polymerase chain reaction) whereas there were 25 (37.3%) such individuals among the RIBA-4 positive donors (P < 0.0005). Twenty (80%) of the latter 25 RIBA-4 positive donors with possible hepatitis C consented to liver biopsy. Of these 20 donors, 11 (55.0%) were found to have chronic persistent hepatitis, four (20.0%) mild, three (15.0%) moderate, and two (10.0%) severe chronic active hepatitis.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:7521901 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7521901 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7521901 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7521901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7521901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7521901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7521901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7521901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7521901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7521901 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7521901 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:7521901 | pubmed:issn | 0146-6615 | lld:pubmed |
| pubmed-article:7521901 | pubmed:author | pubmed-author:KrusiusTT | lld:pubmed |
| pubmed-article:7521901 | pubmed:author | pubmed-author:IkkalaEE | lld:pubmed |
| pubmed-article:7521901 | pubmed:author | pubmed-author:FärkkiläMM | lld:pubmed |
| pubmed-article:7521901 | pubmed:author | pubmed-author:MäkinenJJ | lld:pubmed |
| pubmed-article:7521901 | pubmed:author | pubmed-author:NaukkarinenRR | lld:pubmed |
| pubmed-article:7521901 | pubmed:author | pubmed-author:KolhoEE | lld:pubmed |
| pubmed-article:7521901 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7521901 | pubmed:volume | 43 | lld:pubmed |
| pubmed-article:7521901 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7521901 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7521901 | pubmed:pagination | 129-34 | lld:pubmed |
| pubmed-article:7521901 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:meshHeading | pubmed-meshheading:7521901-... | lld:pubmed |
| pubmed-article:7521901 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7521901 | pubmed:articleTitle | Clinical significance of hepatitis C antibodies in blood donors. | lld:pubmed |
| pubmed-article:7521901 | pubmed:affiliation | Finnish Red Cross Blood Transfusion Service, Helsinki. | lld:pubmed |
| pubmed-article:7521901 | pubmed:publicationType | Journal Article | lld:pubmed |
